Multidrug resistant Enterobacteriaceae and extended spectrum β-lactamase producing Escherichia coli: a cross-sectional study in National Kidney Center, Nepal

Antimicrobial Resistance and Infection Control

Kamlesh Kumar Yadav³  Nabaraj Adhikari³  Rama Khadka³  Anil Dev Pant¹  Bibha Shah² 

[1] Consultant pathologist, National Kidney Center, Vanasthali, Kathmandu, Nepal

[2] Quality Control Department, Qmed Formulations Pvt. Ltd., Chhaling, Bhaktapur, Nepal

[3] Department of Microbiology, Kantipur College of Medical Science, Sitapaila, Kathmandu, Nepal

关键词: UTI;    Urine;    Nepal;    Multidrug resistance;    ESBL;    Enterobacteriaceae;    E. coli;    Antibiotic resistance;   

Others  :  1234950
DOI  :  10.1186/s13756-015-0085-0

 received in 2015-08-10, accepted in 2015-10-15,  发布年份 2015

【 摘 要 】

Background

Emergence of antibacterial resistance and production of Extended spectrum β-lactamases (ESBLs) are responsible for the frequently observed empirical therapy failures. Most countries have experienced rapid dissemination of ESBLs producing Enterobacteriaceae isolates, particularly E. coli and Klebsiella pneumoniae. ESBLs are clinically significant and when detected, indicate the need for the use of appropriate antibacterial agents. But antibacterial choice is often complicated by multi-resistance.

Methods

This study was carried from June to November 2014 to study the multidrug resistant (MDR) Enterobacteriaceae and ESBL producing E. coli among urine isolates in hospital setting. Isolates from urine samples were primarily screened for possible ESBL production followed by phenotypic confirmation. Antibiotic susceptibility testing (AST) was done by Kirby Bauer disk diffusion method following Clinical and Laboratory Standard Institute (CLSI) guidelines.

Results

Out of 450 urine samples processed, 141 significant growths were obtained including 95 Enterobacteriaceae isolates with 67 E. coli. Among Enterobacteriaceae, 92 (96.84 %) were recorded as MDR and 18 (26.87 %) E. coli were confirmed as ESBLs producers.

Conclusions

Using the phenotypic confirmatory test forwarded by the CLSI, relatively significant E. coli isolates tested were ESBL producers. Also high numbers of MDR organisms were isolated among Enterobacteriaceae. Isolates showed significant resistance to the commonly prescribed drugs. These findings suggest for further study in this field including the consequences of colonization with MDR and ESBL-producing bacteria both in the community and in the hospital setting.

【 授权许可】

   
2015 Yadav et al.

【 参考文献 】

• [1]Kattel HP, Acharya J, Mishra SK, Rijal BP, Pokhrel BM. Bacteriology of urinary tract infection among patients attending Tribhuvan University Teaching Hospital, Kathmandu, Nepal. J Nepal Assoc Med Lab Sci. 2008; 9:25-9.
• [2]Nachimuthu R, Sumathi CS, Balasubramanian V, Palaniappan KR, Kannan VR. Urinary tract infection and antimicrobial susceptibility pattern of extended spectrum of beta lactamase producing clinical isolates. Adv Biol Res. 2008; 2:78-82.
• [3]Thirapanmethee K. Extended spectrum β-lactamases: critical tools of bacterial resistance. Mahidol Univ J Pharm Sci. 2012; 39:1-8.
• [4]Bradford PA. Extended-Spectrum β-Lactamases in the 21st Century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001; 14:933-51.
• [5]Mukherjee M, Basu S, Mukherjee SK, Majumder M. Multidrug-resistance and extended spectrum beta-lactamase production in uropathogenic E. coli which were isolated from hospitalized patients in Kolkata, India. J Clin Diagn Res. 2013; 7:449-53.
• [6]Chander A, Shrestha CD. Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal. BMC Res Notes. 2013; 6:487-92. BioMed Central Full Text
• [7]Chaudhary U, Aggarwal R. Extended spectrum β-lactamases (ESBL) - An emerging threat to clinical therapeutics. Indian J Med Microbiol. 2004; 22:75-80.
• [8]Sahuquillo-Arce JM, Perpinan H, Armero C, Lopez-Quilez A, Selva M, Gonzalez F. Bayesian Approach to Urinary ESBL-Producing Escherichia coli. J Pharmacovigilance. 2014; 2:133.
• [9]Cohen Stuart J, Dierikx C, Al Naiemi N, Karczmarek A, Van Hoek AHAM, Vos P et al.. Rapid detection of TEM, SHV and CTX-M extended-spectrum β-lactamases in Enterobacteriaceae using ligation-mediated amplification with microarray analysis. J Antimicrob Chemother. 2010; 65:1377-81.
• [10]Tambekar DH, Dhanorkar DV, Gulhane SR, Khandelwal VK, Dudhane MN. Antibacterial susceptibility of some urinary tract pathogens to commonly used antibiotics. Afr J Biotechnol. 2006; 5:1562-65.
• [11]Mena A, Plasencia V, García L, Hidalgo O, Ayestarán JI, Alberti S et al.. Characterization of a Large Outbreak by CTX-M-1-Producing Klebsiella pneumoniae and Mechanisms Leading to In Vivo Carbapenem Resistance Development. J Clin Microbiol. 2006; 44:2831.
• [12]Performance Standards for Antimicrobial Susceptibility Testing. CLSI: M100-S25, USA; 2015. Wayne, PA
• [13]Maina D, Makau P, Nyerere A, Revathi G. Antimicrobial resistance patterns in extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae isolates in a private tertiary hospital, Kenya. Microb Discov. 2013; 1:5.
• [14]Sharma AR, Bhatta DR, Shrestha J, Banjara MR. Antimicrobial Susceptibility Pattern of Escherichia coli isolated from Urinary Tract Infected Patients Attending Bir Hospital. Nepal J Sci Technol. 2013; 14:177-84.
• [15]Moyo SJ, Aboud S, Kasubi M, Lyamuya EF, Maselle SY. Antimicrobial resistance among producers and non-producers of extended spectrum beta-lactamases in urinary isolates at a tertiary Hospital in Tanzania. BMC Res Notes. 2010; 3:348-52. BioMed Central Full Text
• [16]Simon H. Urinary Tract Infection. 2015. http://pennstatehershey. adam.com/content.aspx?productId=10&pid=10&gid=000036. Accessed 05 Sep 2015
• [17]Dhakal S, Manandhar S, Shrestha B, Dhakal R, Pudasaini M. Extended spectrum β-lactamase producing multidrug resistant urinary isolates from children visiting Kathmandu Model Hospital. Nepal Med Coll J. 2012; 14:136-41.
• [18]Ahmed OB, Omar AO, Asghar AH, Elhassan MM. Increasing prevalence of ESBL-producing Enterobacteriaceae in Sudan community patients with UTIs. Egypt Acad J Biolog Sci. 2013; 5:17-24.
• [19]Acharya A, Gautam R, Subedee L. Uropathogens and their antimicrobial susceptibility pattern in Bharatpur, Nepal. Nepal Med Coll J. 2011; 13:30-3.
• [20]Khawcharoenporn T, Vasoo S, Singh K. Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency Department. Hindawi Publishing Corporation Emergency Medicine International. 2013; doi:10.1155/2013/258517
• [21]Thakur S, Pokhrel N, Sharma N. Prevalence of Multidrug Resistant Enterobacteriaceae and Extended Spectrum β Lactamase Producing Escherichia Coli in Urinary Tract Infection. RJPBCS. 2013; 4:1615-24.
• [22]Sorum H, Sunde M. Resistance to antibiotics in the normal flora of animals. Vet Res. 2001; 32:227-41.
• [23]Kandeel A. Prevalence and risk factors of extended-spectrum β-lactamses producing Enterobacteriaceae in a general hospital in Saudi Arabia. JMID. 2014; 4:50-4.
• [24]Roshan M, Ikram A, Mirza IA, Malik N, Abbasi SA, Alizai SA. Susceptibility Pattern of Extended Spectrum ß-Lactamase Producing Isolates in Various Clinical Specimens. J Coll Physicians Surg Pak. 2011; 21:342-6.
• [25]Shah AA, Hasan F, Ahmed S, Hameed A. Extended-spectrum beta-lactamases in Enterobacteriaceae: related to age and gender. New Microbiol. 2002; 25:363-6.
• [26]Rajan S, Prabavathy J. Antibiotic Sensitivity and Phenotypic Detection of ESBL producing E. coli Strains Causing Urinary Tract Infection In a Community Hospital, Chennai, Tamil Nadu, India. WebmedCentral. Pharm Sci. 2012; 3: Article ID WMC003840
• [27]Mumtaz S, Ahmad M, Aftab I, Akhtar N, ul Hassan M, Hamid A. Extended spectrum β-lactamases in enteric gram-negative bacilli: related to age and gender. JAMC. 2007; 19:107-11.
• [28]Khanfar HS, Bindayna KM, Senok AC, Botta GA. Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. J Infect Dev Ctries. 2009; 3:295-9.
• [29]Islam MS, Yusuf MA, Islam MB, Jahan WA. Frequency of ESBL in Surgical Site Infection at a Tertiary Care Hospital. J Curr Adv Med Res. 2014; 1:25-9.
• [30]Sompolinsky D, Nitzan Y, Tetry S, Wolk M, Vulikh I, Kerrn MB et al.. Integron-mediated ESBL resistance in rare serotypes of Escherichia coli causing infections in an elderly population of Israel. J Antimicrob Chemother. 2005; 55:119-22.
• [31]Wani KA, Thakur MA, Fayaz AS, Fomdia B, Gulnaz B, Maroof P. Extended Spectrum B-Lactamase Mediated Resistance in Escherichia Coli in a Tertiary Care Hospital. Int J Health Sci (Qassim). 2009; 3:155-63.
• [32]Gonzalez US, Spencer JP. Aminoglycosides: a practical review. Am Fam Physician. 1998; 58:1811-20.
• [33]Nepal Public Health Laboratory (NPHL). Dissemination of important findings of Anti Microbial Resistance Surveillance programme. http://www.nphl.gov.np/index.php?obj=content&id=161. Accessed 22 June 2014.
• [34]Kader AA, Angamuthu K. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia. Saudi Med J. 2005; 26:956-9.
• [35]Mekki AH, Hassan AN, Elsayed DEM. Extended spectrum beta lactamase among multi drug resistant E. coli and Klebsiella species causing urinary tract infections in Khartoum. J Bact Res. 2010; 2:18-21.
• [36]Smet A, Martel A, Persoons D, Dewulf J, Heyndrickx M, Herman L et al.. Broad-spectrum β-lactamases among Enterobacteriaceae of animal origin: molecular aspects, mobility and impact on public health. FEMS Microbiol Rev. 2010; 34:295-316.
• [37]Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med. 2006; 119:S20-S28.
• [38]Paterson DL, Ko WC, Gottberg AV, Casellas JM, Mulazimoglu L, Klugman KP et al.. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001; 39:2206-12.
• [39]Shah AA, Hasan F, Ahmed S, Hameed A. Prevalence of extended spectrum β-lactamases in nosocomial and outpatients (ambulatory). Pak J Med Sci. 2003; 19:187-91.